title: Lung blood flow must be considered when prescribing a long-acting β2-agonist/inhaled corticosteroid combination.
authors.affiliation: Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy; Department of Pulmonary Rehabilitation, San Raffaele Pisana, Rome, Italy. Electronic address: mario.cazzola@uniroma2.it.
authors.forename: Mario
authors.initials: M
authors.lastname: Cazzola
authors.affiliation: Department of Experimental Medicine, Second University, Naples, Italy.
authors.forename: Maria Gabriella
authors.initials: MG
authors.lastname: Matera
mesh_terms: D000403:Airway Resistance / Q000187:drug effects*; D000420:Albuterol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000730:Androstadienes / Q000627:therapeutic use*; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D001980:Bronchi / Q000098:blood supply*; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D000068298:Fluticasone; D000068297:Fluticasone-Salmeterol Drug Combination; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009130:Muscle, Smooth / Q000187:drug effects*; D009131:Muscle, Smooth, Vascular / Q000187:drug effects*; D000068299:Salmeterol Xinafoate; D014664:Vasodilation / Q000187:drug effects*
chemical_list: D000730:Androstadienes; D018927:Anti-Asthmatic Agents; D001993:Bronchodilator Agents; D004338:Drug Combinations; D000068297:Fluticasone-Salmeterol Drug Combination; D005938:Glucocorticoids; D000068299:Salmeterol Xinafoate; D000068298:Fluticasone; D000420:Albuterol